Everolimus, 10 mg

An mTOR pathway inhibitor marketed under the alternative names RAD001, SDZ-RAD, and Xience is available from STEMCELL Technologies as a crystalline solid. The compound is described as a hydroxyethyl ether-substituted derivative of Rapamycin, and it inhibits both mTORC1 and mTORC2 complexes by binding to FKBP-12, with reported immunosuppressive and anti-neoplastic effects.

Reported properties include a chemical formula of C₅₃H₈₃NO₁₄, a molecular weight of 958.2 g/mol, a purity of ≥ 95%, and a CAS number of 159351-69-6. The solid is stable at -20°C as supplied for 12 months from the date of receipt and should be protected from prolonged exposure to light. Reported solubility is ≤ 100 mM in DMSO and ≤ 100 mM in absolute ethanol, with low solubility in aqueous media.

According to the manufacturer's published applications, the compound has been used as an immunosuppressive agent in the context of organ transplantation, and in cancer research to inhibit cell proliferation, metabolism, and angiogenesis in a variety of cancers using in vitro and in vivo models.